DrugPatentWatch Database Preview
Capmatinib hydrochloride - Generic Drug Details
» See Plans and Pricing
What are the generic sources for capmatinib hydrochloride and what is the scope of freedom to operate?
Capmatinib hydrochloride
is the generic ingredient in one branded drug marketed by Novartis Pharm and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Capmatinib hydrochloride has one hundred and thirty-seven patent family members in forty countries.
One supplier is listed for this compound.
Summary for capmatinib hydrochloride
| International Patents: | 137 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Clinical Trials: | 11 |
| DailyMed Link: | capmatinib hydrochloride at DailyMed |
Recent Clinical Trials for capmatinib hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Novartis Pharmaceuticals | Phase 3 |
| Commissariat A L'energie Atomique | Phase 3 |
| Plateforme labellisée Inca – Institut Bergonié, Bordeaux | Phase 3 |
US Patents and Regulatory Information for capmatinib hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis Pharm | TABRECTA | capmatinib hydrochloride | TABLET;ORAL | 213591-002 | May 6, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Novartis Pharm | TABRECTA | capmatinib hydrochloride | TABLET;ORAL | 213591-001 | May 6, 2020 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Novartis Pharm | TABRECTA | capmatinib hydrochloride | TABLET;ORAL | 213591-002 | May 6, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Novartis Pharm | TABRECTA | capmatinib hydrochloride | TABLET;ORAL | 213591-001 | May 6, 2020 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Novartis Pharm | TABRECTA | capmatinib hydrochloride | TABLET;ORAL | 213591-002 | May 6, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Novartis Pharm | TABRECTA | capmatinib hydrochloride | TABLET;ORAL | 213591-001 | May 6, 2020 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for capmatinib hydrochloride
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 3034075 | Start Trial |
| Canada | 2669991 | Start Trial |
| Ecuador | SP10010685 | Start Trial |
| China | 103288833 | Start Trial |
| South Korea | 101532256 | Start Trial |
| European Patent Office | 2099447 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
